Potentiation of radiation-induced growth inhibition by letrozole measured by cell-count assay

<p><b>Copyright information:</b></p><p>Taken from "Letrozole sensitizes breast cancer cells to ionizing radiation"</p><p>Breast Cancer Research 2004;7(1):R156-R163.</p><p>Published online 7 Dec 2004</p><p>PMCID:PMC1064115.</p><p>Copyright © 2004 Azria et al., licensee BioMed Central Ltd.</p> Growth of MCF-7CA cells, measured for 18 days after treatment, was inhibited to a 76% greater extent with letrozole plus 4 Gy radiation after 12 days, and to an 85% greater extent after 18 days, compared with radiation alone. Solid lines, ■ and ◆ represent radiation alone at 2 Gy and 4 Gy, respectively; dotted lines, ■ and ◆ represent combination of radiation plus letrozole (0.7 μM) at 2 Gy and 4 Gy, respectively

Potentiation of radiation-induced growth inhibition by letrozole measured by the MTT assay

<p><b>Copyright information:</b></p><p>Taken from "Letrozole sensitizes breast cancer cells to ionizing radiation"</p><p>Breast Cancer Research 2004;7(1):R156-R163.</p><p>Published online 7 Dec 2004</p><p>PMCID:PMC1064115.</p><p>Copyright © 2004 Azria et al., licensee BioMed Central Ltd.</p> Growth of MCF-7CA cells, measured 6 days after treatment, was inhibited to a 40% greater extent with letrozole plus 2 Gy radiation, and to a 76% greater extent with letrozole plus 4 Gy radiation, compared with radiation alone

Potentiation of radiation-induced growth inhibition by letrozole measured by clonogenic assay

<p><b>Copyright information:</b></p><p>Taken from "Letrozole sensitizes breast cancer cells to ionizing radiation"</p><p>Breast Cancer Research 2004;7(1):R156-R163.</p><p>Published online 7 Dec 2004</p><p>PMCID:PMC1064115.</p><p>Copyright © 2004 Azria et al., licensee BioMed Central Ltd.</p> With radiation alone the MCF-7CA cell survival fraction decreased in a dose-dependent manner, which was significantly potentiated by the addition of 0.7 μM letrozole. For 2 Gy radiation, the surviving fraction was 0.66 with radiation alone and was 0.46 with the addition of letrozole (= 0.02). For 3 Gy radiation, the corresponding surviving fractions were 0.4 and 0.18, respectively (= 0.02)

Homogeneity index (HI) for each patient in the coplanar field CF (grey) and non coplanar field NCF (black) technique

<p><b>Copyright information:</b></p><p>Taken from "Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer"</p><p>http://www.ro-journal.com/content/2/1/35</p><p>Radiation Oncology (London, England) 2007;2():35-35.</p><p>Published online 18 Sep 2007</p><p>PMCID:PMC2072954.</p><p></p> HI is defined as the difference between D1 and D99% divided by the prescribed dose. A perfect homogeneity would be reached with a zero index

Mean dose volume histogram in the planning target volume for the coplanar field CF (grey) and non coplanar field technique NCF (black)

<p><b>Copyright information:</b></p><p>Taken from "Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer"</p><p>http://www.ro-journal.com/content/2/1/35</p><p>Radiation Oncology (London, England) 2007;2():35-35.</p><p>Published online 18 Sep 2007</p><p>PMCID:PMC2072954.</p><p></p> Minimum and maximum doses of the study group are represented by dotted lines

PTV mean dose volume histogram in the T4 subgroup for the coplanar field CF (grey) and non coplanar field technique NCF (black)

<p><b>Copyright information:</b></p><p>Taken from "Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer"</p><p>http://www.ro-journal.com/content/2/1/35</p><p>Radiation Oncology (London, England) 2007;2():35-35.</p><p>Published online 18 Sep 2007</p><p>PMCID:PMC2072954.</p><p></p> Minimum and maximum doses of the study group are represented by dotted lines

Maximum doses in optic pathways, respectively optic chiasma (a), ipsilateral optic nerve (b) and controlateral optic nerve (c)

<p><b>Copyright information:</b></p><p>Taken from "Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer"</p><p>http://www.ro-journal.com/content/2/1/35</p><p>Radiation Oncology (London, England) 2007;2():35-35.</p><p>Published online 18 Sep 2007</p><p>PMCID:PMC2072954.</p><p></p> For each patient (Px), the maximum dose for coplanar field CF (grey) and for non coplanar field NCF (black) is represented

Dose distribution in optic pathways for each patient (Px); optic chiasma (a), ipsilateral optic nerve (b) and controlateral optic nerve (c) respectively

<p><b>Copyright information:</b></p><p>Taken from "Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer"</p><p>http://www.ro-journal.com/content/2/1/35</p><p>Radiation Oncology (London, England) 2007;2():35-35.</p><p>Published online 18 Sep 2007</p><p>PMCID:PMC2072954.</p><p></p> The dose difference in Gy between non coplanar field NCF and coplanar field CF (D NCF – D CF) is represented in terms of D1%, D2%, and D5% corresponding to the doses in 1, 2 and 5 % of the volumes respectively. This means that when the difference is negative, the dose to optic pathways is higher when using coplanar field technique

Conformal index CI for each patient in the coplanar field CF (grey) and non coplanar field NCF (black) technique

<p><b>Copyright information:</b></p><p>Taken from "Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer"</p><p>http://www.ro-journal.com/content/2/1/35</p><p>Radiation Oncology (London, England) 2007;2():35-35.</p><p>Published online 18 Sep 2007</p><p>PMCID:PMC2072954.</p><p></p> CI is defined as follows: CI = (TV/V) × (TV/V) TV: Treated Volume is the volume of PTV1 receiving the prescribed dose (95%); Vis the volume of PTV; Vis the volume enclosed in the isodose 95